Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.60    3.80 (2.49%)
Bid:
156.40
Ask:
156.80
Spread: 0.40 (0.256%)
Market Cap: £896.25m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Q3 Trading Update

25 Oct 2018 07:00

RNS Number : 1088F
Elementis PLC
25 October 2018
 

Elementis plc

Q3 Trading Update

 Resilient overall performance, confident of continued progress in 2018

Elementis plc ("Elementis" or the "Group"), a global Specialty Chemicals Company, today issues its period end trading update for the three months ended 30 September 2018.

The Group has delivered resilient performance in the third quarter, and overall is on track and confident of making further financial and strategic progress in 2018.

Business Performance

· In Personal Care solid performance in the period was supported by growth in sales to direct customers of our unique, high margin hectorite based products and the successful delivery of SummitReheis synergies.

 

· In Coatings our transformation programme continues to gather pace as we optimise the product portfolio, implement efficiency measures and execute price increases. In Q3, performance in Europe and the Americas was similar to the first half but Asia has been impacted by weaker volumes and currency headwinds, primarily in China, as a result of an economic slowdown.

 

· Activity levels in Energy have improved driven by new business and early signs of recovery in deep water drilling. We continue to expect a sequential improvement in performance in the second half of the year.

 

· In Chromium, as previously communicated, production at Castle Hayne was temporarily suspended in September due to Hurricane Florence and subsequent flooding. Production has since restarted, and whilst we expect some mitigation from insurance, this outage will adversely impact Chromium full year operating performance. Otherwise, demand remains strong with supportive pricing momentum expected in 2019.

Mondo Minerals Acquisition

Completion of the Mondo Minerals acquisition on 23 October represents a material new growth opportunity for Elementis. In 2018 Mondo continues to trade in line with our expectations, and is experiencing good momentum going into 2019.

Strong cash generation

Elementis' strong free cash generation continued in Q3 and was enhanced by the disposal of our Jersey City site for $17m in August. Including the sale of the Surfactants business in February, this brings cumulative proceeds from asset disposals to over $60m in 2018.

Having completed the acquisition of Mondo Minerals, a material deleveraging profile is envisaged for the Group and this will be accelerated by the outcome of the triennial review of the UK pension scheme that concluded no cash top up payments are required from Elementis until at least 2021. This contrasts to the previous three years where total contributions were $32m.

 

Commenting on the performance, CEO, Paul Waterman said,

 

"Overall performance in the third quarter has been solid. We continue to implement our Reignite Growth strategy, focusing resources on higher margin growth opportunities, high grading our business portfolio and driving both cost and capital efficiency. In addition we are excited to begin the integration of Mondo Minerals at pace. "

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

Martin Robinson/David Allchurch, Tulchan Tel: 020 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTMIBLTMBATBAP
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.